On September 13, 2021 Taiho Oncology, Inc. which specializes in orally administered anti-cancer medicines and whose mission is to improve the lives of patients with cancer, their families and their caregivers, reported data presentations from several studies for two of its investigational agents at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2021 (Press release, Taiho, SEP 13, 2021, View Source [SID1234587643]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Three abstracts have been selected for poster presentations, including for futibatinib (TAS-120) in advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA) and gastric cancer, and for TAS-117 in advanced solid tumors.
"These presentations support the Company’s focus on developing agents that target the underlying genetic abnormalities in a variety of tumors," said Martin J. Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. "The burden for patients living with different forms of cancers continues to remain high, and we are committed to advancing the science to address ongoing and unmet therapeutic needs."
Key data on investigational anti-cancer agents from Taiho Oncology at the ESMO (Free ESMO Whitepaper) Congress 2021 include:
Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA): Funda Meric-Bernstam, MD, Chair of the Department of Investigational Cancer Therapeutics – the Phase I Program at MD Anderson Cancer Center and Medical Director of the Institute for Personalized Cancer Therapy (IPCT) (51P). Results will be shared as a poster presentation on September 16, 2021. The abstract for this presentation is available on the ESMO (Free ESMO Whitepaper) website: View Source;c=pnr
Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA): Antoine Hollebecque, MD, Senior Medical Physician, Gustave Roussy Cancer Center, Paris (52P). Results will be shared as a poster presentation on September 16, 2021. The abstract for this presentation is available on the ESMO (Free ESMO Whitepaper) website: View Source;c=pnr
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations: Jordi Rodon Ahnert, MD, PhD, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (559TiP). Results will be shared as a poster presentation on September 16, 2021. The abstract for this presentation is available on the ESMO (Free ESMO Whitepaper) website: View Source;c=pt
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational anti-cancer futibatinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions. The FDA Office of Orphan Drug Development has also granted futibatinib orphan drug status for the treatment of cholangiocarcinoma.
Taiho Pharmaceutical Co., Ltd., Taiho Oncology’s parent company, will also present the following data:
Phase 1 study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: updated dose expansion results and activity in gastric cancer: Y. Kuboki, MD, PhD, Chief Physician, Department of Experimental Therapeutics and Head, Clinical Research Coordination Division, National Cancer Center Hospital East, Kashiwa, Japan (1383P). Results will be shared as a poster presentation on September 16, 2021. The abstract for this presentation is available on the ESMO (Free ESMO Whitepaper) website: View Source;c=pnr
About Futibatinib (TAS-120)
Futibatinib (TAS-120) is an investigational, oral, potent, selective, and irreversible small-molecule inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarcinoma, who were previously treated with chemotherapy or other therapies. Futibatinib was designed to selectively and irreversibly bind to the ATP binding pocket of FGFR1-4. It aims to inhibit FGFR-mediated signal transduction pathways, reduce tumor cell proliferation and increase tumor cell death in tumors with FGFR1-4 genetic aberrations.
Futibatinib has not been approved by the U.S. FDA or any other regulatory agency worldwide for the uses under investigation.
About Cholangiocarcinoma
Cholangiocarcinoma (CCA) is also known as bile duct cancer. It includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) cancers. CCA can occur at younger ages, but it is seen mainly in older people.
About TAS-117
TAS-117 is a highly potent and selective oral allosteric AKT inhibitor that inhibits kinase activity of AKT1/2/3 and phosphorylation of downstream substrates. TAS-117 is currently being investigated globally in multiple clinical trials in patients with advanced solid tumors.
TAS-117 has not been approved by the U.S. FDA or any other regulatory agency worldwide for the uses under investigation.